Does holding at 1.7 mg for sixteen weeks before escalating reduce dizziness?

Numbers first: 1.7 mg · sixteen weeks · dizziness.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

Can someone derive this rather than assert it?

sixteen weeks at 1.7 mg is 112 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1.7 mg back by 112 days. Whether that reduces dizziness depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1.7 mg is 1.7 mg on day 1 and on day 112. A symptom driven by the rate of change has 112 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot dizziness against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

The part that matters: liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Slower costs time and nothing else. The ceiling is the same.

The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.

The caveat is that titration decisions belong with a clinician who knows what else is on board.

Hold rather than escalate while symptoms are active. Always.

The short version: four-weekly steps for the weekly agents, hold rather than escalate when symptoms are active, and slower is always available.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

Stated carefully, the dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

Stepping back is a normal adjustment, not a failure.

The relevant detail is that this is the single most consequential controllable variable in the whole experience, and people routinely rush it.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

The top of the schedule is not the target. The working dose is.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Four half-lives between steps, minimum. Work it out for your agent.

edited 31 May 2026 by samir_bennani — clarified the distinction between purity and content